NeoX Therapeutics to Present Preclinical Data on IL-21 Fc Fusion Protein NXC03 and WEE1 Degrader at AACR-NCI-EORTC 2023

The 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, jointly organized by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organization for Research and Treatment of Cancer (EORTC), will be held in Boston, USA, from October 11 to 15, 2023. The AACR-NCI-EORTC symposium will bring together academics, scientists, and representatives from pharmaceutical companies worldwide to discuss the latest advances in drug development, target selection, and the impact of new discoveries in molecular biology. At the conference, neoX Biotech will present its latest preclinical research findings on IL-21 Fc fusion protein and WEE1 protein degrader in poster format. NXC03, a proprietary attenuated IL-21 mutant designed by artificial intelligence at neoX Biotech, demonstrates potent anti-tumor activity and has the potential to become an immunostimulant used in combination with immune checkpoint inhibitors.